Form 4: Enanta Pharma CEO Covers Taxes with Stock Forfeiture
Insider Transaction Report
Enanta Pharmaceuticals' President and CEO, Jay R. Luly, disposed of 1,885 shares of common stock to cover tax withholding obligations related to a restricted stock unit settlement.
Summary
- Jay R. Luly, President and CEO, and a Director of Enanta Pharmaceuticals Inc. (ENTA), reported a transaction on December 1, 2025.
- The transaction involved the disposition of 1,885 shares of ENTA common stock.
- These shares were forfeited to cover withholding taxes due to the settlement of a portion of a restricted stock unit (RSU) award.
- The RSU award was originally granted on November 19, 2021.
- The shares were disposed of at a price of $14.12 per share.
- Following this transaction, Jay R. Luly beneficially owns 862,769 shares of ENTA common stock directly.
- The transaction was made pursuant to a Rule 10b5-1 plan.
Sentiment
Score: 5
Explanation: The filing reports a routine, tax-related insider transaction that is neutral in sentiment. It reflects a standard part of executive compensation and does not indicate positive or negative developments for the company's operations or financial health.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing details a routine insider transaction related to executive compensation and tax obligations, which is common across all industries, particularly for publicly traded companies with RSU programs. It does not provide specific insights into broader industry trends or competitive landscape for the pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase or sale of equity securities. This indicates a pre-arranged trading plan designed to comply with insider trading regulations. | 12/01/2025 | The use of a 10b5-1 plan demonstrates adherence to corporate governance best practices regarding insider trading, providing an affirmative defense against claims of trading on material non-public information. |
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, tax-related transaction and not a discretionary sale. The change in beneficial ownership is minor relative to total outstanding shares.
- Employees: No direct impact on general employees.
- Management: The transaction is a standard part of the CEO's compensation structure, reflecting the vesting and tax obligations of previously granted equity awards.
Key Dates
| Date | Description |
|---|---|
| 11/19/2021 | Date of grant for the restricted stock unit award. |
| 12/01/2025 | Transaction date for the forfeiture of common stock. |
| 12/03/2025 | Signature date of the reporting person's attorney-in-fact. |
Keywords
Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Stock Forfeiture, Restricted Stock Units, Executive Compensation, Tax Withholding, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.